EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Renewable Energy Solutions for Pharma Factories: Powering Sustainable Pharmaceutical Manufacturing

    One of the most energyconsuming sectors of the industrial sector is the pharmaceutical manufacturing Energy requirement in the pharma factories is continuous and critical whether it is controlled environments and cleanrooms continuous production lines HVAC system cold storage as well as quality testing laboratories With the increasing regulatory pressure ESG undertakings and the cost of energy ren...

    EU Pharma Reform 2025 Explained: What Market Access Leaders Must Know for 2026-2029

    What if your EU market exclusivity depends on launching your medicine in every member state and proving its realworld value This is no longer hypothetical The historic Pharma Reform agreement of the Council of the EU of March is the first major revision of pharmaceutical legislation in more than years It will have a significant impact on the way businesses will enter the market set their prices...

    Chiral Biosensors: Precision Tools for Safer Drugs

    The pharmaceutical industry has long been recognised the profound implications of chirality in drug design and development Enantiomers mirrorimage isomers of a chiral molecule show dramatically distinct pharmacokinetic PK and pharmacodynamic PD profiles One may be therapeutically active while its counterpart could be inactive or harmful As a result the precise detection discrimination and quantifi...

    7 B2B Pharma Display Ad Strategies That Actually Drive Leads (2026 Guide)

    Theres a quiet frustration most pharma marketers dont say out loud display ads should work better than they do Budgets go in Impressions look fine CTRs are acceptable And yet pipeline barely moves

    Considerations and Functional Elements of Closed Systems: Isolators and Single Use Systems

    Advances in technology have demonstrated the feasibility of using isolators and singleuse systems SUS in routine pharmaceutical manufacturing operations particularly in aseptic processing Their implementation has significantly reduced the risk of chemical particulate and microbiological contamination

    Why Biopharma is switching to Single-Use Systems: Cost, Quality, and Flexibility

    Singleuse biopharma systems have replaced traditional stainlesssteel systems in the biopharmaceutical industry because of a major industry transformation What factors lead the market toward this direction Major factors that drive the industry involve establishing savings from singleuse equipment in pharmaceutical applications

TOP ARTICLES

  • 2

    Chiral Biosensors: Precision Tools for Safer Drugs

    Dr. Selvakumar Kanthiah

    Dr. Valliappan Kannappan

    In drug development, identifying the right mirror-image molecule - called an enantiomer - can be the difference between a life-saving treatment and unwanted side effects. Chiral biosensors are revolut...

press releases Read more...

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Ionis Pharmaceuticals Inc Nasdaq IONS partner Novartis today announced that the pelacarsen Phase LpaHORIZON study a pioneering cardiovascular outcomes trial did not meet its primary endpoint

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis today announced that the pelacarsen phase III LpaHORIZON trial a pioneering cardiovascular outcomes study did not meet its primary endpoint of reducing the risk of cardiovascular events a composite

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio Inc Nasdaq CLYM a clinicalstage biotechnology company developing therapeutics for patients with immunemediated diseases today announced positive initial data from the ongoing

Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program

Applied Biologics a biopharmaceutical company advancing novel therapies for serious diseases with significant unmet medical needs today announced an important preclinical milestone in its DiseaseModifying

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

LATEST NEWS Read more...

AtomVie opens new radiopharmaceutical manufacturing facility in Ontario

AtomVie Global Radiopharma AtomVie has opened a new purposebuilt radiopharmaceutical manufacturing facility in Hamilton Ontario strengthening its capacity to support drug development and commercial production

Acepodia receives FDA clearance for ACE723 antibody-drug conjugate

Acepodia a clinicalstage biotechnology company developing cell therapies and antibodydrug conjugates ADCs has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for ACE

Kali Therapeutics Receives U.S. FDA Clearance for KT501 Clinical Trial

Kali Therapeutics a clinicalstage biotechnology company developing immuneresetting and multispecific therapies has received clearance from the US Food and Drug Administration FDA for its Investigational New

Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development

Genedata has expanded its collaboration with Abcam to strengthen antibody development and support the use of artificial intelligence AI across Abcams global research and development operations

Evotec and Plectonic Enter Research Collaboration to Explore New T-Cell-Engaging Approaches for Solid Tumours

Evotec SE and Plectonic Biotech have entered a research collaboration to explore a new immunotherapy approach for solid tumours The partnership will combine Plectonics programmable LOGIBODY

NewBiologix and Synastra Biotechnology Partner to Advance Stable rAAV Manufacturing for Duchenne Muscular Dystrophy Gene Therapy

NewBiologix SA and Synastra Biotechnology Inc have entered into an agreement to develop a stable producer cell line for Synastras investigational gene therapy programme for Duchenne muscular dystrophy DMD